Answers are grounded in this paper and cite their sources.
The selective serotonin reuptake inhibitor fluvoxamine has high binding affinity for the Sigma-1 receptor, an intracellular chaperone protein modulating neuroplasticity and pro-survival pathways. We set out to examine the effects of fluvoxamine in mouse models of dopaminergic degeneration driven by neurotoxin-induced damage or seeded alpha-synuclein aggregation. In mice with unilateral 6-hydroxydopamine lesions, five weeks of daily treatment with fluvoxamine at the doses of 0.3 or 20 mg/kg/day gradually restored contralateral forelimb use and partially protected nigral dopaminergic neurons while reducing the number of phagocytically activated microglia. In addition, the larger dose significantly increased the density of dopaminergic fibers in the dopamine-depleted striatum. These beneficial effects were absent in Sigma-1 receptor knockout mice. We next evaluated the 20 mg/kg dose in mice inoculated with preformed alpha-synuclein fibrils in the striatum, starting treatment one month post-surgery and administering it daily for four months. Although fluvoxamine did not alter the formation of alpha-synuclein inclusions, it promoted a regenerative response in the nigrostriatal pathway, increasing dopaminergic fiber density in the depleted striatum and markedly reducing the number of activated microglia in the substantia nigra. The results from both parkinsonian models demonstrate that fluvoxamine treatment stimulates fiber regrowth in the damaged nigrostriatal system while inhibiting microglial overactivation. These findings support Sigma-1 receptors as a potential target for disease-modifying therapies in Parkinson's disease and point to fluvoxamine as a relevant repurposing candidate.
No takes yet. Share an insight, caveat, or question.
Cesaroni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: